Terms and Conditions

The Pulmozyme Voucher Program

The Pulmozyme Voucher ("Voucher") is a Free Trial offer that may only be used with a valid prescription of Pulmozyme. The Voucher does not obligate use or continuing use of Pulmozyme or any provider. This Voucher is only valid for prescriptions filled in United States and U.S. Territories and is void where prohibited by law. The Voucher may only be fulfilled through participating retail and specialty pharmacies.

By using the Voucher, the patient acknowledges and confirms that at the time of usage, they are currently eligible and meet the criteria set forth in the terms and conditions described. Patients must have a valid prescription for an FDA approved indication for Pulmozyme. Patients under the age of 18 must be enrolled by their Legal Guardian.

Patients CANNOT submit a claim from the Pulmozyme Voucher Program, to any federal healthcare program including Medicare, Medicaid, Veteran's Affairs (VA), Department of Defense (DOD), TRICARE or any other federal or state programs, under any private insurance, HMO, or other third party payment arrangement for reimbursement, or (b) to count toward your out-of-pocket cost under your prescription drug plan, or (c) to count toward a pre-tax HealthCare or Flex Spending Account (HSA or FSA).

The Voucher provides up to 30-day supply of Pulmozyme at $0 to the patient. Patients are limited to receive one voucher at the start of their treatment with Pulmozyme. Healthcare providers may not advertise or otherwise use the program as a means of promoting their services or Genentech's product to patients. This Voucher cannot be combined with any other rebate, coupon, free trial, or similar offer for the specified prescription. This voucher expires 12 months from the date it is activated. The Voucher may not be sold, purchased, traded, or offered for sale, purchase, or trade. This Voucher is not health insurance or a benefit plan. Genentech reserves the right to rescind, revoke, or amend the Voucher Program without notice at any time.

The Pulmozyme Co-pay Program

This Pulmozyme Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid, Medigap, Veteran's Affairs (VA), Department of Defense (DoD), TRICARE or any other federal or state government program to pay for their medications are not eligible. The Program is not valid for medications that are eligible to be reimbursed in their entirety by private insurance plans or other programs.

Under the Program, the patient will pay a co-pay. After reaching the maximum Program benefit, the patient will be responsible for all out-of-pocket costs. This Program is not health insurance or a benefit plan. The Program does not obligate the use of any specific product or provider. Patients receiving assistance from charitable assistance programs (such as Genentech Patient Foundation) are not eligible. The Co-pay benefit cannot be combined with any other rebate, free trial, or similar offer for the medication. No party may seek reimbursement for all or any part of the benefit received through this Program.

The Program may be accepted by participating pharmacies, physician offices, or hospitals. Once enrolled, this Program will not honor claims with date of service or medication dispensing that precede Program enrollment by more than 120 days. Use of this Program must be consistent with all relevant health insurance requirements. Participating patients, pharmacies, physician offices, and hospitals are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. Program benefits may not be sold, purchased, traded, or offered for sale, purchase, or trade.

The patient or their guardian must be 18 years or older for the patient to be eligible. This Program is only valid in the United States and U.S. Territories. This Program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g. MA, CA) where applicable. Program eligibility is contingent upon the patient's ability to meet and maintain all requirements set forth by the Program. Genentech reserves the right to rescind, revoke, or amend the Program without notice at any time.

Important Safety Information & Indication


Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.